12 research outputs found
Methods to Discover and Evaluate Proteasome Small Molecule Stimulators
Protein accumulation has been identified as a characteristic of many degenerative conditions, such as neurodegenerative diseases and aging. In most cases, these conditions also present with diminished protein degradation. The ubiquitin-proteasome system (UPS) is responsible for the degradation of the majority of proteins in cells; however, the activity of the proteasome is reduced in these disease states, contributing to the accumulation of toxic protein. It has been hypothesized that proteasome activity, both ubiquitin-dependent and -independent, can be chemically stimulated to reduce the load of protein in diseased cells. Several methods exist to identify and characterize stimulators of proteasome activity. In this review, we detail the ways in which protease activity can be enhanced and analyze the biochemical and cellular methods of identifying stimulators of both the ubiquitin-dependent and -independent proteasome activities
AI is a viable alternative to high throughput screening: a 318-target study
: High throughput screening (HTS) is routinely used to identify bioactive small molecules. This requires physical compounds, which limits coverage of accessible chemical space. Computational approaches combined with vast on-demand chemical libraries can access far greater chemical space, provided that the predictive accuracy is sufficient to identify useful molecules. Through the largest and most diverse virtual HTS campaign reported to date, comprising 318 individual projects, we demonstrate that our AtomNet® convolutional neural network successfully finds novel hits across every major therapeutic area and protein class. We address historical limitations of computational screening by demonstrating success for target proteins without known binders, high-quality X-ray crystal structures, or manual cherry-picking of compounds. We show that the molecules selected by the AtomNet® model are novel drug-like scaffolds rather than minor modifications to known bioactive compounds. Our empirical results suggest that computational methods can substantially replace HTS as the first step of small-molecule drug discovery
Recommended from our members
The Role of the Proteasome in Limiting Cellular Stress Associated with Protein Accumulation
Abstract:
The proteasome is comprised of multiple subunits that catalyze the degradation of proteins to maintain cellular homeostasis. The proteasome targets protein substrates by two different pathways. The ubiquitin‐dependent pathway requires proteins to be labeled with a ubiquitin tag to signal for degradation by the 26S isoform of the proteasome. Protein degradation through this pathway declines during age progression. The ubiquitin‐independent pathway utilizes the 20S proteasome isoform. It can degrade misfolded and intrinsically disordered proteins to decrease cellular stress. Age‐related protein accumulation and aggregation can occur due to the decreased activity and expression of the proteasome. Protein accumulation causes increased cellular stress which can contribute to disease progression. Increasing proteasome activity could serve as a solution to eliminating and preventing protein accumulation. Studies have shown the value of the proteasome as a therapeutic entity to mitigate cellular stress. This perspective explores the link between proteasome activity and cellular stress caused by age‐related misfolded protein accumulation
Taming of a Superbase for Selective Phenol Desilylation and Natural Product Isolation
Hydroxyl moieties are highly prevalent
in natural products. We
previously reported a chemoselective strategy for enrichment of hydroxyl-functionalized
molecules by formation of a silyl ether bond to a resin. To generate
smaller pools of molecules for analysis, we developed cleavage conditions
to promote stepwise release of phenolic silyl ethers followed by aliphatic
silyl ethers with a “tamed” version of the superbase
1,1,3,3–tetramethylguanadine. We demonstrate this as a general
strategy for selective deprotection of phenolic silyl ethers under
neutral conditions at room temperature
Development and Application of a Sensitive Peptide Reporter to Discover 20S Proteasome Stimulators
To attenuate an overabundance
of cellular protein, it has been
hypothesized that the 20S core particle (20S CP) of the proteasome
can be chemically stimulated to degrade proteins into nontoxic peptides
more quickly. Screening for small molecule 20S CP stimulators is typically
performed with a reporter peptide composed of four amino acids and
a coumarin group that is released upon proteasome-mediated hydrolysis
to generate a fluorescent signal. Screening with this small reporter
can lead to false negatives because the reporter peptide is rapidly
turned-over without stimulation. To improve the screening for 20S
CP stimulators, we have developed a peptide FRET reporter nearly four
times more sensitive to stimulation but still amenable for high throughput
screening. Through application of our FRET reporter, we have discovered
two 20S CP gate-opening stimulators and also a molecule that elicits
its mechanism of action through an interaction with a 20S CP active
site
Fluorescent Probes with Unnatural Amino Acids to Monitor Proteasome Activity in Real-Time
The proteasome is an essential protein complex that, when dysregulated, can result in various diseases in
eukaryotic cells. As such, understanding the enzymatic activity of the proteasome and what can alter it is crucial
to elucidating its roles in these diseases. This can be done effectively by using activity-based fluorescent
substrate probes, of which there are many commercially available that target the individual protease-like subunits
in the 20S CP of the proteasome. Unfortunately, these probes have not displayed appropriate characteristics for
their use in live cell-based assays. In the work presented here, we have developed a set of probes which have
shown improved fluorescence properties and selectivity towards the proteasome compared to other cellular
proteases. By including unnatural amino acids, we have found probes which can be utilized in various
applications, including monitoring the effects of small molecule stimulators of the proteasome in live cells and
comparing the relative proteasome activity across different cancer cell types. In future studies, we expect the
fluorescent probes presented here will serve as tools to support the discovery and characterization of small
molecule modulators of proteasome activity.
</div
Fluorescent Probes with Unnatural Amino Acids to Monitor Proteasome Activity in Real-Time
Rubiscolins are naturally occurring G protein-biased delta opioid receptor peptides
The impact that β-arrestin proteins have on G protein-coupled receptor trafficking, signaling and physiological behavior has gained much appreciation over the past decade. A number of studies have attributed the side effects associated with the use of naturally occurring and synthetic opioids, such as respiratory depression and constipation, to excessive recruitment of β-arrestin. These findings have led to the development of biased opioid small molecule agonists that do not recruit β-arrestin, activating only the canonical G protein pathway. Similar G protein-biased small molecule opioids have been found to occur in nature, particularly within kratom, and opioids within salvia have served as a template for the synthesis of other G protein-biased opioids. Here, we present the first report of naturally occurring peptides that selectively activate G protein signaling pathways at δ opioid receptors, but with minimal β-arrestin recruitment. Specifically, we find that rubiscolin peptides, which are produced as cleavage products of the plant protein rubisco, bind to and activate G protein signaling at δ opioid receptors. However, unlike the naturally occurring δ opioid peptides leu-enkephalin and deltorphin II, the rubiscolin peptides only very weakly recruit β-arrestin 2 and have undetectable recruitment of β-arrestin 1 at the δ opioid receptor
Hyperexcitability and Pharmacological Responsiveness of Cortical Neurons Derived from Human iPSCs Carrying Epilepsy-Associated Sodium Channel Nav1.2-L1342P Genetic Variant.
With the wide adoption of genomic sequencing in children having seizures, an increasing number of SCN2A genetic variants have been revealed as genetic causes of epilepsy. Voltage-gated sodium channel Nav1.2, encoded by gene SCN2A, is predominantly expressed in the pyramidal excitatory neurons and supports action potential (AP) firing. One recurrent SCN2A genetic variant is L1342P, which was identified in multiple patients with epileptic encephalopathy and intractable seizures. However, the mechanism underlying L1342P-mediated seizures and the pharmacogenetics of this variant in human neurons remain unknown. To understand the core phenotypes of the L1342P variant in human neurons, we took advantage of a reference human-induced pluripotent stem cell (hiPSC) line from a male donor, in which L1342P was introduced by CRISPR/Cas9-mediated genome editing. Using patch-clamping and microelectrode array (MEA) recordings, we revealed that cortical neurons derived from hiPSCs carrying heterozygous L1342P variant have significantly increased intrinsic excitability, higher sodium current density, and enhanced bursting and synchronous network firing, suggesting hyperexcitability phenotypes. Interestingly, L1342P neuronal culture displayed a degree of resistance to the anticonvulsant medication phenytoin, which recapitulated aspects of clinical observation of patients carrying the L1342P variant. In contrast, phrixotoxin-3 (PTx3), a Nav1.2 isoform-specific blocker, can potently alleviate spontaneous and chemically-induced hyperexcitability of neurons carrying the L1342P variant. Our results reveal a possible pathogenic underpinning of Nav1.2-L1342P mediated epileptic seizures and demonstrate the utility of genome-edited hiPSCs as an in vitro platform to advance personalized phenotyping and drug discovery.SIGNIFICANCE STATEMENT A mounting number of SCN2A genetic variants have been identified from patients with epilepsy, but how SCN2A variants affect the function of human neurons contributing to seizures is still elusive. This study investigated the functional consequences of a recurring SCN2A variant (L1342P) using human iPSC-derived neurons and revealed both intrinsic and network hyperexcitability of neurons carrying a mutant Nav1.2 channel. Importantly, this study recapitulated elements of clinical observations of drug-resistant features of the L1342P variant, and provided a platform for in vitro drug testing. Our study sheds light on cellular mechanism of seizures resulting from a recurring Nav1.2 variant, and helps to advance personalized drug discovery to treat patients carrying pathogenic SCN2A variant